Physician profile
Arijit Chakravarty
NPI 1386778199
$18,877.30
in general payments reported to CMS, 2019-2025
21 companies · $80.25 in 2025
The $80.25 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $75.95 · 2021: $4,878 · 2022: $11K · 2023: $2,127 · 2024: $256 · 2025: $80.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,509 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $722 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $722.00 |
| Education | $231.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15,828.32 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $665.70 | 2020-2025 | Acthar |
| Fresenius USA Marketing, INC. | $348.86 | 2021-2024 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $314.01 | 2020-2024 | Jynarque |
| Opko Pharmaceuticals, LLC | $259.82 | 2022-2023 | Rayaldee |
| Glaxosmithkline, LLC. | $212.24 | 2021-2023 | Benlysta |
| Travere Therapeutics, INC. | $175.22 | 2023-2024 | |
| Amgen INC. | $171.40 | 2019-2024 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $162.14 | 2020-2023 | Farxiga |
| Vifor Pharma, INC. | $147.76 | 2019-2023 | Veltassa, Korsuva |
| Shionogi INC | $144.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $123.76 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $81.39 | 2021-2022 | |
| Novo Nordisk INC | $50.00 | 2024 | Wegovy |
| Horizon Therapeutics Plc | $46.52 | 2023 | Krystexxa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $46.35 | 2022-2023 | Tarpeyo |
| Ardelyx, INC. | $29.15 | 2023 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.18 | 2023 | Jardiance |
| Nxstage Medical, INC. | $19.94 | 2025 | Liberty Select Cycler, Nxstage System One |
| Lilly USA, LLC | $13.59 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $11.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arijit Chakravarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.